|
시장보고서
상품코드
2049507
핵산 검사 시장 보고서 : 제품 유형별, 기술별, 최종사용자별, 지역별(2026-2034년)Nucleic Acid Testing Market Report by Product Type, Technology, End User, and Region 2026-2034 |
||||||
세계의 핵산 검사 시장 규모는 2025년에 34억 달러에 달했습니다. 향후 IMARC Group은 2034년까지 시장 규모가 54억 달러에 달하고, 2026년부터 2034년까지 CAGR 5.18%로 성장할 것으로 예측했습니다.
핵산 검사(NAT)는 환자의 혈액, 조직 또는 소변에서 바이러스, 박테리아 또는 병원성 핵산을 스크리닝하는 분자 기술을 말합니다. 법의학 검사, 수혈 감염, 유전성 질환, 암 진단을 위해 시행됩니다. 이 검사에는 핵산(NA) 추출을 통한 검체 풀링, 표적 NA 증폭, 표적 증폭 산물의 NA 검출이 포함됩니다. 이 검사에는 중합효소 연쇄 반응(PCR), 사슬치환증폭(SDA), 리가제연쇄반응(LCR), 전사매개증폭(TMA), 핵산 서열기반증폭(NASBA) 과정을 수행하기 위한 키트와 소모품이 포함됩니다. NAT는 또한 눈에 보이는 증상이 없는 질병을 식별하고 위양성 판정을 해결하는 데도 사용됩니다.
전 세계적으로 세균성 및 바이러스성 감염증의 유병률이 증가하고 있는 것은 시장 성장을 이끄는 주요 요인 중 하나입니다. 또한, 첨단 진단 시스템에 대한 수요 증가도 시장 성장을 촉진하고 있습니다. 이에 따라 신종 코로나바이러스 감염증(COVID-19)의 발생도 항원 검출을 위한 NAT 솔루션에 대한 수요를 높이고 있습니다. NAT는 감염증의 효과적인 관리와 감염 요인의 정확한 규명을 위해 널리 활용되고 있습니다. 또한, 신호 증폭 시스템 및 프로브 증폭 시스템을 포함한 새로운 생물학적 진단 기술 개발 등 다양한 기술 발전도 시장 성장을 촉진하는 요인으로 작용하고 있습니다. 이러한 혁신적인 기술은 질병의 조기 발견과 바이러스 감염 기간 단축에 기여합니다. 또한, 광범위한 연구개발(R&D) 활동과 의료 인프라 개선 등 다른 요인들도 시장 확대를 견인할 것으로 예상됩니다.
본 보고서에서 답변하는 주요 질문
- 지금까지의 세계 핵산 검사 시장의 동향은 어떠했으며, 향후 몇 년 동안 어떻게 변화할 것인가?
- COVID-19는 세계 핵산 검사 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은 어디인가?
- 제품 유형별 시장 구성은 어떠한가?
- 기술별로 보면 시장 분석은 어떻게 이루어지는가?
- 최종사용자별 시장 분석은 어떻게 이루어지고 있는가?
- 이 산업의 가치사슬에서 각 단계는 어떤 역할을 하는가?
- 이 산업의 주요 촉진요인과 과제는 무엇인가?
- 세계 핵산 검사 시장의 구조는 무엇이며, 주요 플레이어는 누구인가?
- 업계 내 경쟁은 어느 정도 치열한가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 핵산 검사 시장
제6장 시장 내역 : 제품 유형별
제7장 시장 내역 : 기술별
제8장 시장 내역 : 최종사용자별
제9장 시장 내역 : 지역별
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
KSM 26.06.10The global nucleic acid testing market size reached USD 3.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 5.4 Billion by 2034, exhibiting a growth rate (CAGR) of 5.18% during 2026-2034.
Nucleic acid testing (NAT) refers to a molecular technique for screening viruses, bacteria or pathogenic nucleic acid in the blood, tissue or urine of the patient. It is conducted for forensic testing and to diagnose transfusion-transmitted infections, genetic diseases and cancer. It involves sample pooling through nucleic acid (NA) extraction, target NA amplification and target amplicon NA detection. The testing involves kits and consumables for performing polymerase chain reaction (PCR), strand displacement amplification (SDA), ligase chain reaction (LCR), transcription-mediated amplification (TMA) and NA sequence-based amplification (NASBA) processes. NAT is also used for the identification of diseases with no visible symptoms and resolving false reactive interpretations.
The increasing prevalence of infectious bacterial and viral diseases across the globe represents one of the key factors driving the growth of the market. Furthermore, the increasing demand for advanced diagnostic systems is also driving the market growth. In line with this, the onset of the coronavirus disease (COVID-19) has also enhanced the demand for NAT solutions to detect the antigens. NAT is widely used for the effective management of communicable diseases and accurate identification of the infecting agent. Additionally, various technological advancements, such as the development of novel biological diagnostic techniques, including signal and probe amplification systems, are acting as other growth-inducing factors. These innovative techniques aid in the early detection of the disease and minimizing the infectious period of the virus. Other factors, including extensive research and development (R&D) activities, along with improvements in the healthcare infrastructure, are anticipated to drive the market further.
KEY MARKET SEGMENTATION:
Breakup by Product Type:
- Instruments
- Reagents and Consumables
Breakup by Technology:
- TMA- Transcription-mediated Amplification
- PCR- Polymerase Chain Reaction
- LCR- Ligase Chain Reaction
- SDA- Strand Displacement Amplification
- Others
Breakup by End User:
- Hospitals and Clinics
- Pathology Laboratories
- Research Institutes
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Agilent Technologies, Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Illumina Inc., Merck KGaA, Siemens Healthcare, Tecan Group AG and Thermo Fisher Scientific Inc.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How has the global nucleic acid testing market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global nucleic acid testing market?
- What are the key regional markets?
- What is the breakup of the market based on the product type?
- What is the breakup of the market based on the technology?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global nucleic acid testing market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Nucleic Acid Testing Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product Type
- 6.1 Instruments
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Reagents and Consumables
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Technology
- 7.1 TMA- Transcription-mediated Amplification
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 PCR- Polymerase Chain Reaction
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 LCR- Ligase Chain Reaction
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 SDA- Strand Displacement Amplification
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals and Clinics
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Pathology Laboratories
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Research Institutes
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Agilent Technologies
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Becton, Dickinson and Company
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Bio-Rad Laboratories Inc.
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Danaher Corporation
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 F. Hoffmann-La Roche Ltd.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 SWOT Analysis
- 14.3.7 Illumina Inc.
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Merck KGaA
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Siemens Healthcare
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.10 Tecan Group AG
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.11 Thermo Fisher Scientific Inc.
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.11.4 SWOT Analysis
- 14.3.1 Abbott Laboratories
